BI, Click Therapeutics in $500-M-Plus Pact for Digital TherapeuticBy
Boehringer Ingelheim (BI) and Click Therapeutics, a New York-based developer of software as prescription medical treatments, have formed a collaboration, worth up more than $500 million, for the development and commercialization of a prescription-based digital therapeutic.
The prescription-based digital therapeutic will use cognitive and neurobehavioral mechanisms delivered through Click’s proprietary engagement platform with the goal of reducing cognitive deficits and impaired social functioning in patients with schizophrenia. Under the agreement, BI and Click Therapeutics will develop a novel mobile application, CT-155, which combines multiple clinically validated therapeutic interventions to help schizophrenia patients modify their behavior to achieve positive clinical outcomes alone and in combination with pharmaceutical therapy options.
Under the agreement, Click Therapeutics will be primarily responsible for research and development activities, and BI receives exclusive global commercial rights to CT-155. Click Therapeutics will receive an upfront payment and funding for research and development activities as well as for clinical, regulatory, and commercial milestones for a total deal value of more than $500 million. Additionally, Click Therapeutics will receive tiered royalties on annual net sales of CT-155 globally.